This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (25)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Diabetes Mellitus  • Alert me on articles by topic  Social Bookmarking   What's this?

The Independent Effect of Plasminogen Activator Inhibitor 1

Alka M. Kanaya, MD; Christina Wassel Fyr, MS; Eric Vittinghoff, PhD; Tamara B. Harris, MD; Seok Won Park, PhD; Bret H. Goodpaster, PhD; Fran Tylavsky, PhD; Steven R. Cummings, MD

Arch Intern Med. 2006;166:350-356.

Background  Adipose tissue produces "adipocytokines" of uncertain clinical significance.

Methods  We analyzed the relationships among adiposity, adipocytokines, glycemia, and incident diabetes mellitus in 2356 white and black adults aged 70 to 79 years in the Health, Aging, and Body Composition Study who did not have diabetes at baseline. We measured the levels of adipocytokines adiponectin, leptin, interleukin 6, tumor necrosis factor , and plasminogen activator inhibitor 1. Regional fat area was determined by means of computed tomography. New diabetes was defined as a self-reported diagnosis of diabetes or as a fasting plasma glucose level of 126 mg/dL or greater (7.0 mmol/L) at the second, fourth, or sixth annual examination.

Results  A total of 143 participants (14.1 cases per 1000 person-years) developed diabetes across 5 years. Visceral fat area (odds ratio [OR], 1.33; 95% confidence interval [CI], 1.10-1.60 per standard deviation increase) and body mass index (white individuals: OR, 1.65; 95% CI, 1.26-2.15 per standard deviation increase; black individuals: OR, 1.22; 95% CI, 0.99-1.51 per standard deviation increase) independently predicted incident diabetes. Adiponectin, leptin, and plasminogen activator inhibitor 1 attenuated the relationship between adiposity and diabetes. After controlling for body mass index, visceral fat, fasting glucose, fasting insulin, high-density lipoprotein cholesterol, triglycerides, and hypertension at baseline, plasminogen activator inhibitor 1 was the only adipocytokine independently associated with increased odds of diabetes (OR, 1.35; 95% CI, 1.01-1.81). Fasting glucose level at baseline remained a strong predictor of incident diabetes, whereas associations with body mass index and visceral fat were attenuated.

Conclusions  Adipocytokines and glycemia partially account for the relationship between adiposity and risk of type 2 diabetes due to adiposity. Plasminogen activator inhibitor 1 may be a useful predictor of diabetes in addition to measurements of body fat.

Author Affiliations: Division of General Internal Medicine, Department of Medicine (Dr Kanaya), Women's Health Clinical Research Center (Drs Kanaya, Vittinghoff, and Cummings and Ms Wassel Fyr), and Department of Epidemiology and Biostatistics (Drs Kanaya, Vittinghoff, and Cummings), University of California, San Francisco; Laboratory of Epidemiology, Demography, and Biometry, Intramural Research Program, National Institutes of Health, Bethesda, Md (Dr Harris); Division of Endocrinology and Metabolism, Department of Medicine (Dr Goodpaster), and Department of Epidemiology (Dr Park), University of Pittsburgh, Pittsburgh, Pa (Drs Park and Goodpaster); and Department of Preventive Medicine, University of Tennessee, Memphis (Dr Tylavsky).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Fetuin-A and Change in Body Composition in Older Persons
Ix et al.
J. Clin. Endocrinol. Metab. 2009;94:4492-4498.
ABSTRACT | FULL TEXT  

Cytokine and Cytokine-Like Inflammation Markers, Endothelial Dysfunction, and Imbalanced Coagulation in Development of Diabetes and Its Complications
Goldberg
J. Clin. Endocrinol. Metab. 2009;94:3171-3182.
ABSTRACT | FULL TEXT  

Five-Year Change in Visceral Adipose Tissue Quantity in a Minority Cohort: The Insulin Resistance Atherosclerosis Study (IRAS) Family Study
Hairston et al.
Diabetes Care 2009;32:1553-1555.
ABSTRACT | FULL TEXT  

Adiponectin Levels and Risk of Type 2 Diabetes: A Systematic Review and Meta-analysis
Li et al.
JAMA 2009;302:179-188.
ABSTRACT | FULL TEXT  

Cross-Sectional Associations Bet ween Abdominal and Thoracic Adipose Tissue Compartments and Adiponectin and Resistin in the Framingham Heart Study
Jain et al.
Diabetes Care 2009;32:903-908.
ABSTRACT | FULL TEXT  

Adipocytokines and the Metabolic Complications of Obesity
Rasouli and Kern
J. Clin. Endocrinol. Metab. 2008;93:s64-s73.
ABSTRACT | FULL TEXT  

Adipokines and Incident Type 2 Diabetes in an Aboriginal Canadian Population: The Sandy Lake Health and Diabetes Project
Ley et al.
Diabetes Care 2008;31:1410-1415.
ABSTRACT | FULL TEXT  

Thrombospondin-1 Is an Adipokine Associated With Obesity, Adipose Inflammation, and Insulin Resistance
Varma et al.
Diabetes 2008;57:432-439.
ABSTRACT | FULL TEXT  

4G/5G Plasminogen Activator Inhibitor-1 Polymorphisms and Haplotypes Are Associated with Pneumonia
Yende et al.
Am. J. Respir. Crit. Care Med. 2007;176:1129-1137.
ABSTRACT | FULL TEXT  

Association of Plasminogen Activator Inhibitor (PAI)-1 (SERPINE1) SNPs With Myocardial Infarction, Plasma PAI-1, and Metabolic Parameters: The HIFMECH Study
Morange et al.
Arterioscler. Thromb. Vasc. Bio. 2007;27:2250-2257.
ABSTRACT | FULL TEXT  

Adipokines and Risk of Type 2 Diabetes in Older Men
Wannamethee et al.
Diabetes Care 2007;30:1200-1205.
ABSTRACT | FULL TEXT  

PAI-1 and the Metabolic Syndrome: Links, Causes, and Consequences
Alessi and Juhan-Vague
Arterioscler. Thromb. Vasc. Bio. 2006;26:2200-2207.
ABSTRACT | FULL TEXT